RxDoctor Payments Data

Damon Forbes, MD

Critical Care Medicine · Fort Bragg, NCNPI 1932335452

Payments from drug & device makers

$332in general payments, 2019–2025

Across 13 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$125
  • Insmed, Inc.$64
  • United Therapeutics Corporation$40
  • Pharming Healthcare, Inc.$21
  • AstraZeneca$20
  • Genentech USA, Inc.$18
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$31695%
  • Education$165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$332 in reported general payments places this provider in the 50th percentile of 190 critical care medicine providers in North Carolina.

See all critical care medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$91,826
Medicare patients
349
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter131$123,510
Pirfenidone11$31,650
Spiriva RespimatTiotropium Bromide37$30,303
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$28,528
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$21,321
Advair HfaFluticasone Propion/Salmeterol28$15,754
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$13,786
Spiriva HandihalerTiotropium Bromide15$12,306
Breo ElliptaFluticasone/Vilanterol29$12,172
SymbicortBudesonide/Formoterol Fumarate31$11,262
Albuterol Sulfate HfaAlbuterol Sulfate126$5,414
Ipratropium Bromide66$2,359
Roflumilast20$2,077
Ventolin HfaAlbuterol Sulfate32$1,951
Azithromycin48$534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$15$164,211199 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$125$44,08963 claims
AstraZenecaBreztri Aerosphere, Symbicort$20$32,58351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 190 critical care medicine providers in North Carolina.

Other critical care medicine in Fort Bragg

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →